In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program

Antimicrobial Agents and Chemotherapy
James A KarlowskyDaniel F Sahm

Abstract

Relebactam is a non-β-lactam, bicyclic diazabicyclooctane β-lactamase inhibitor of class A and class C β-lactamases, including Klebsiella pneumoniae carbapenemases (KPCs). It is in phase 3 clinical development in combination with imipenem/cilastatin. The in vitro activities of imipenem-relebactam, imipenem, and comparators were determined using the Clinical and Laboratory Standards Institute (CLSI) reference broth microdilution method for isolates of Enterobacteriaceae (n = 3,419) and Pseudomonas aeruginosa (n = 896) collected in 2016 by 21 U.S. hospital laboratories participating in the SMART (Study for Monitoring Antimicrobial Resistance Trends) global surveillance program. Relebactam was tested at a fixed concentration of 4 μg/ml. Imipenem-relebactam MICs were interpreted using CLSI breakpoints for imipenem. Rates of susceptibility to imipenem-relebactam and imipenem for non-ProteeaeEnterobacteriaceae (n = 3,143) and P. aeruginosa were 99.1% (3,115/3,143) and 95.9% (3,013/3,143) and were 94.4% (846/896) and 74.7% (669/896), respectively. Relebactam restored imipenem susceptibility to 78.5% (102/130) of imipenem-nonsusceptible non-ProteeaeEnterobacteriaceae and to 78.0% (177/227) of imipenem-nonsusceptible P. aeruginosa isola...Continue Reading

References

May 21, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·O ZarkotouA Tsakris
Jul 29, 2011·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·A-P MagiorakosD L Monnet
Dec 12, 2012·International Journal of Antimicrobial Agents·Karen BushDeidre Jarrett
Dec 12, 2012·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Dawn M SievertUNKNOWN National Healthcare Safety Network (NHSN) Team and Participating NHSN Facilities
May 23, 2013·The Journal of Antimicrobial Chemotherapy·David M LivermoreShazad Mushtaq
Nov 8, 2014·Journal of Clinical Microbiology·Twisha S Patel, Jerod L Nagel
Mar 7, 2015·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·J M PogueD Marchaim
Apr 13, 2015·European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology·I Olsen
May 28, 2015·Antimicrobial Agents and Chemotherapy·Amabel LapueblaJohn Quale
Mar 30, 2016·International Journal of Antimicrobial Agents·Sibylle H LobRobert E Badal
Oct 22, 2016·Infection Control and Hospital Epidemiology : the Official Journal of the Society of Hospital Epidemiologists of America·Lindsey M WeinerDawn M Sievert
Apr 6, 2017·The Journal of Antimicrobial Chemotherapy·Katie L HopkinsNeil Woodford
Sep 13, 2017·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·H WrightD L Paterson
Sep 30, 2017·The Journal of Antimicrobial Chemotherapy·David M LivermoreNeil Woodford

❮ Previous
Next ❯

Citations

Feb 15, 2019·Frontiers in Microbiology·Chau-Chyun SheuPo-Ren Hsueh
May 16, 2019·The Journal of Antimicrobial Chemotherapy·Sibylle H LobDaniel F Sahm
Oct 22, 2020·Research : a Science Partner Journal·Zifang ShangWei Huang
Oct 4, 2020·Current Opinion in Infectious Diseases·Abigail K KoisJoseph L Kuti
Jul 28, 2020·Expert Opinion on Pharmacotherapy·Mohamad MoussaAthanasios Papatsoris
Dec 4, 2020·Infection and Drug Resistance·Toni A Campanella, Jason C Gallagher
Nov 13, 2020·Clinical Microbiology Reviews·Dafna YahavLeonard Leibovici
Oct 13, 2021·Current Opinion in Infectious Diseases·Matteo BassettiDaniele Roberto Giacobbe

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.